REGERALD

ZEIGE O

30 September 2005

BY COURIER

US Securities and Exchange Commiss.....
Division of Corporate Finance
Office of International Corporate Finance
Mail Stop 3-2
450 Fifth Street NW
Washington DC 20549
USA

Ark Therapeutics Group Plc 79 New Cavendish Street London WIW 6XB Tel: +44 (0)20 7388 7722 Fax: +44 (0)20 7388 7805 www.arktherapeutics.com

Therap

SUPPL

Ark Therapeutics Group plc, Rule 12g3-2(b) Exemption, File No. 82-34804

To whom it may concern:

Please find enclosed information and/or documents furnished on behalf of Ark Therapeutics Group plc, Rule 12g3-2(b) File No. 82-34804, submitted pursuant to paragraph (b)(1)(iii) of Rule 12g3-2, which information shall not be deemed "filed" with the SEC or otherwise subject to the liabilities of Section 18 of the US Securities Exchange Act of 1934.

Sincerely,

Nick Plummer

General Counsel & Company Secretary

Ark Therapeutics Group plc

PROCESSED

OCT 18 2005

THOMSON THOMSON

De 10/3

Kuopio

London

Registered Office: 79 New Covendish Street London WIW 6XB,UK Registered in England 4313987 FILE NO: 82-34804



1.	DOCUMENTS MADE PUBLIC PURSUANT TO LAWS OF ENGLAND AND WALES SINCE SEPTEMBER 1, 2005
1.1	Form 288c – Change of Particulars for Director or Secretary dated September 8, 2005 in respect of Dr Bruce Carter
1.2	Form 88(2) - Return of Allotment of Shares dated September 29, 2005
2.	DOCUMENTS FILED WITH THE UKLA OR THE LSE (AND MADE PUBLIC THEREBY) SINCE SEPTEMBER 1, 2005
2.1	Miscellaneous Notifications filed with The London Stock Exchange
2.1.1	Announcement dated September 9, 2005 regarding Holding(s) in Company
2.1.2	Announcement dated September 9, 2005 regarding Holding(s) in Company
2.1.3	Announcement dated September 13, 2005 regarding Holding(s) in Company
2.1.4	Announcement dated September 26, 2005 regarding Change of Adviser
3.	PRESS RELEASES SINCE SEPTEMBER 1, 2005
3.1	Press release dated September 26, 2005 regarding Change of Adviser (see 2.1.4 above)



Please complete in typescript, or in bold black capitals.

CHWP000

CHANGE OF PARTICULARS for director

or secretary(NOT for appointment (use Form 288a) or resignation (use Form 288b))

(Com	na	nv	Nii	mh	or
,	- OIII	שמ	117	IYU		'eı

	Company Number	4313987			
Co	mpany Name in full	ARK THERAPEUTICS GROUP P	LC		
Changes of			Day Month Year		
Changes of particulars	Complete in all cases	Date of change of particulars	7 0 9 2 0 0 5		
form	Name *Style / Title	Dr *H	onours etc		
	Forename(s)	Bruce			
	Surname	Carter			
		Day Month Year			
	† Date of Birth	1 4 0 6 1 9 4 3			
Change of name (e	enter new name) Forename(s)				
	Surname				
Change of usual residential address †† (enter new address)		79 New Cavendish Street			
†† Tick this box if the	Post town	London			
address shown is a service address for the beneficiary of a	County / Region		Postcode W1W 6XB		
Confidentiality Order granted under the provisions of section 723B of the	Country	UK			
Companies Act 1985	Other change (please specify)				
		A serving director, secretary etc	must sign the form below.		
* Voluntary details. † Directors only. **Poleto as appropriate	Signed	N.f. Chunner	Date 8/9/05		
Delete as appropriate		(director / secretary /-administrator / administ	rative receiver / receiver manager / receiver)		
You do not have to give any contact information in the box opposite but if you do, it will help Companies House to contact		Nick Plummer, Ark Therapeutics Group plc, 79 New Cavendish Street,			
you if there is a q	uery on the form. The	London W1W 6XB			
contact information that you give will be visible to searchers of the public record		Tel 0207 388 7722			
			change		
Companies Hous	e receipt date barcode	When you have completed and sign Registrar of Companies at:	ned the form please send it to the		
This form has been provided free of charge by Companies House		Companies House, Crown Way, Cardiff, CF14 3UZ DX 33050 Cardiff for companies registered in England and Wales or Companies House, 37 Castle Terrace, Edinburgh, EH1 2EB			

for companies registered in Scotland

Form April 2002

DX 235 Edinburgh or LP - 4 Edinburgh 2



Return of Allotment of Shares

Please complete in typescript, or in bold black capitals. CHWP000

Company Number

4313987

Shares allotted (including bonus shares): From To Date or period during which shares were allotted (If shares were allotted enter that date in the "from" box) Class of shares (ordinary or preference etc) Number allotted Nominal value of each share Amount (if any) paid or due on each share (including any share premium) List the names and addresses of the allottees and the number of shares allotted to each overlean	
Date or period during which shares were allotted (If shares were allotted on one date enter that date in the "from" box) Class of shares (ordinary or preference etc) Number allotted Nominal value of each share Amount (if any) paid or due on each share (including any share premium) From To Day Month Year Day Month ORDINARY ORDINARY \$\frac{2}{6} \text{ 0 9 2 0 0 5} \text{ 0 0 5} 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
Date or period during which shares were allotted (If shares were allotted on one date enter that date in the "from" box) Class of shares (ordinary or preference etc) Number allotted Nominal value of each share Amount (if any) paid or due on each share (including any share premium)	
(ordinary or preference etc) Number allotted Nominal value of each share Amount (if any) paid or due on each share (including any share premium) 500 500 500	Year
Nominal value of each share £0.01 Amount (if any) paid or due on each share (including any share premium) 50p	
Amount (if any) paid or due on each share (including any share premium) 50p	
share (including any share premium)	
List the names and addresses of the allottees and the number of shares allotted to each overlea	
	af .
If the allotted shares are fully or partly paid up otherwise than in cash please sta	ate:
% that each share is to be treated as paid up	
Consideration for which the shares were allotted (This information must be supported by the duly stamped contract or by the duly stamped particulars on Form 88(3) if the contract is not in writing)	

the Registrar of Companies at:

Companies House receipt date barcode

This form has been provided free of charge by Companies House.

Companies House, Crown Way, Cardiff CF14 3UZ For companies registered in England and Wales

DX 33050 Cardiff

DX 235 Edinburgh

Companies House, 37 Castle Terrace, Edinburgh EH1 2EB

For companies registered in Scotland

Shareholder details	Shares and share class allotted		
Name PERSHING KEEN NOMINEES LIMITED	Class of shares allotted	Number allotted	
Address PARTICIPANT ID COL MEMBER ACCOUNT I DOLT	OPPINARY	2.750	
PARTICIPANT ID 601 MEMBER ACCOUNT LDCLT	ORDINARY	3,750	
CAPSTAN HSE, ONE CLOVE CRESCENT, EAST INDIA DOCK, LONDON			
UK Postcode E 1 4 2 B H			
Name	Class of shares allotted	Number allotted	
Address			
		L	
UK Postcode		L	
Name	Class of shares allotted	Number allotted	
Address			
		L	
UK Postcode L L L L L	L	L	
Name	Class of shares allotted	Number allotted	
Address			
	L	·	
UK Postcode	L	<u> </u>	
Name	Class of shares allotted	Number allotted	
Address			
	L		
UK Postcode			
Please enter the number of continuation sheets (if any) attached to this fo	ırm .		
riease enter the number of continuation sheets (if any) attached to this to			
gned Nil Columns Date	29/09/2005		
A director / secretary / administrator / administrative receiver / receiver manager / receiver	Please o	delete as appropriate	
ease give the name, address, lephone number and, if available, DX number and Exchange of the erson Companies House should intact if there is any query. Nick Plummer 79 New Cavendish Street London W1W 6XB Tel: 0207 388 7722			

Company Ark Therapeutics Group PLC

TIDM AKT

Headline Holding(s) in Company Released 15:46 09-Sep-05

Number 1000R

RNS Number: 1000R

Ark Therapeutics Group PLC

09 September 2005

SCHEDULE 10

NOTIFICATION OF MAJOR INTERESTS IN SHARES

1) NAME OF COMPANY

ARK THERAPEUTICS GROUP PLC

2) NAME OF SHAREHOLDER HAVING A MAJOR INTEREST

NOMURA INTERNATIONAL PLC

3) Please state whether notification indicates that it is in respect of holding of the Shareholder named in 2 above or in respect of a non-beneficial interest or in the case of an individual holder if it is a holding of that person's spouse or children under the age of 18

AS IN PARAGRAPH 2 ABOVE

4) Name of the registered holder(s) and, if more than one holder, the number of shares held by each of them.

NORMURA NOMINEES LIMITED PRIN ACCT

5) Number of shares/amount of stock acquired.

NIL

6) Percentage of issued Class

N/A

7) Number of shares/amount of stock disposed

6,000,000

8) Percentage of issued Class

4.71%

9) Class of security

ORDINARY SHARES

- 10) Date of transaction
 - 6 SEPTEMBER 2005
- 11) Date company informed
 - 8 SEPTEMBER 2005

13) Total percentage holding of issued class following this notification 4.75%

14) Any additional information

NICK PLUMMER - +44(0)207 388 7722

15) Name of contact and telephone number for queries

NICK PLUMMER - COMPANY SECRETARY

16) Name and signature of authorised company official responsible for making this notification

Date of Notification 9 SEPTEMBER, 2005

This information is provided by RNS
The company news service from the London Stock Exchange

END

Close

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.

©2005 London Stock Exchange plc. All rights reserved

TIDM AKT

Company

Headline Holding(s) in Company

Ark Therapeutics Group PLC

Released 17:00 09-Sep-05

Number 1068R

RNS Number:1068R

Ark Therapeutics Group PLC

09 September 2005

SCHEDULE 10

NOTIFICATION OF MAJOR INTERESTS IN SHARES

1) NAME OF COMPANY

ARK THERAPEUTICS GROUP PLC

2) NAME OF SHAREHOLDER HAVING A MAJOR INTEREST

THE MERLIN FUND LP

3) Please state whether notification indicates that it is in respect of holding of the Shareholder named in 2 above or in respect of a non-beneficial interest or in the case of an individual holder if it is a holding of that person's spouse or children under the age of 18

HOLDING OF SHAREHOLDER ABOVE

4) Name of the registered holder(s) and, if more than one holder, the number of shares held by each of them.

MERLIN GENERAL PARTNER LIMITED AS GENERAL PARTNER OF THE MERLIN FUND LP MERLIN GENERAL PARTNER LIMITED MBSFLP ACCT

5) Number of shares/amount of stock acquired.

N/A

- 6) Percentage of issued Class N/A
- 7) Number of shares/amount of stock disposed 4,000,000
- 8) Percentage of issued Class
 3.14%
- 9) Class of security

ORDINARY SHARES

10) Date of transaction

8 SEPTEMBER 2005

11) Date company informed

9 SEPTEMBER 2005

12) Total holding following this notification

3,582,290

14) Any additional information

NICK PLUMMER - +44(0)207 388 7722

15) Name of contact and telephone number for queries

NICK PLUMMER - COMPANY SECRETARY

16) Name and signature of authorised company official responsible for making this notification

Date of Notification .. 9 SEPTEMBER 2005.....

This information is provided by RNS
The company news service from the London Stock Exchange

END

Close

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.

©2005 London Stock Exchange plc. All rights reserved

TIDM AKT

Headline Holding(s) in Company
Released 16:37 13-Sep-05

Ark Therapeutics Group PLC

Number 2227R

RNS Number:2227R

Ark Therapeutics Group PLC

13 September 2005

NOTIFICATION OF MAJOR INTERESTS IN SHARES

1) NAME OF COMPANY

ARK THERAPEUTICS GROUP PLC

2) NAME OF SHAREHOLDER HAVING A MAJOR INTEREST

TVM IV GMBH AND CO. KG

3) Please state whether notification indicates that it is in respect of holding of the Shareholder named in 2 above or in respect of a non-beneficial interest

AS IN PARAGRAPH 2 ABOVE

4) Name of registered holder

STATE STREET NOMINEES LIMITED 3BD2 ACCT

5) Number of shares acquired.

N/A

6) Percentage of issued Class

N/A

7) Number of shares disposed

1,000,000

8) Percentage of issued Class

0.79%

9) Class of security

ORDINARY SHARES

10) Date of transaction

12 SEPTEMBER 2005

11) Date company informed

13 SEPTEMBER 2005

12) Total holding following this notification

4,694,000

13) Total percentage holding of issued class following this notification

MARTYN WILLIAMS - +44 (0)207 388 7722

15) Name of company official responsible for making this notification

MARTYN WILLIAMS - CFO

16) Date of Notification

13 SEPTEMBER 2005

This information is provided by RNS
The company news service from the London Stock Exchange

END

Close

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.

@2005 London Stock Exchange plc, All rights reserved

oo to mantot none cootion

Company

Ark Therapeutics Group PLC

TIDM

AKT

Headline

Change of Adviser 18:16 26-Sep-05

Released Number

7813R

26 September 2005

Ark Therapeutics Appoints Piper Jaffray as Joint Financial Adviser and Broker

Ark Therapeutics Group plc (LSE: AKT), the specialist healthcare group, is pleased to announce that it has appointed Piper Jaffray Ltd. as the Company's joint financial adviser and joint broker.

-Ends-

For more information contact:

Ark Therapeutics Group plc

Nigel Parker, CEO / Martyn Williams, CFO

Tel: 020 7388 7722

Financial Dynamics

David Yates / Davina Langdale

Tel: 020 7831 3113

For further information about Ark please see www.arktherapeutics.com

END

Close

London Stock Exchange pic is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.

©2005 London Stock Exchange plc. All rights reserved